Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes

Vaccine

Volumn 29, Issue 35, 2011, Pages 5911-5918

  Pushko, Peter ^a   Pearce, Melissa B ^c   Ahmad, Attiya ^b   Tretyakova, Irina ^a   Smith, Gale ^b   Belser, Jessica A ^c   Tumpey, Terrence M ^c  

^a Medigen Inc   (United States)

^b NOVAVAX INC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Influenza; Influenza vaccine; Trivalent; Virus like particles; VLP

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FERRET; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H2N3); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA A (H7N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N3; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N2; INFLUENZA VIRUS B; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEASONAL INFLUENZA; VIRUS IMMUNITY; VIRUS LIKE AGENT;

ANIMALS; CELLS, CULTURED; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H7N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; SEASONS; SPODOPTERA; VACCINES, SYNTHETIC; VIRION;

EID: 79960728140     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.068     Document Type: Article

References (39)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
2. Fiore A.E., Bridges C.B., Cox N.J. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009, 333:43-82.
3. Ellenberg S.S. Evaluating the safety of combination vaccines. Clin Infect Dis 2001, 33(December (Suppl. 4)):S319-S322.
4. Belser J.A., Blixt O., Chen L.M., Pappas C., Maines T.R., Van Hoeven N., et al. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci USA 2008, 105(May (21)):7558-7563.
5. Yen H.L., Webster R.G. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 2009, 333:3-24.
6. Kang S.M., Pushko P., Bright R.A., Smith G., Compans R.W. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2009, 333:269-289.
7. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001, 75(July (13)):6154-6165.
8. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23(December (50)):5751-5759.
9. Watanabe T., Watanabe S., Neumann G., Kida H., Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002, 76(January (2)):767-773.
10. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PloS one 2008, 3(1):e1501.
11. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009, 83(June (11)):5726-5734.
12. Ross T.M., Mahmood K., Crevar C.J., Schneider-Ohrum K., Heaton P.M., Bright R.A. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PloS one 2009, 4(6):e6032.
13. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(May (19)):3871-3878.
14. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Dev Biol Stand 1977, 39(June):193-200.
15. Mozdzanowska K., Furchner M., Washko G., Mozdzanowski J., Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997, 71(June (6)):4347-4355.
16. Ma W., Vincent A.L., Gramer M.R., Brockwell C.B., Lager K.M., Janke B.H., et al. Identification of H2N3 influenza A viruses from swine in the United States. Proc Natl Acad Sci USA 2007, 104(December (52)):20949-20954.
17. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005, 79(September (18)):11788-11800.
18. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(July (30)):4771-4776.
19. Relman D.A. Bioterrorism-preparing to fight the next war. N Engl J Med 2006, 354(January (2)):113-115.
20. O'Neill E., Donis R.O. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Curr Top Microbiol Immunol 2009, 333:83-108.
21. Palache B., Krause R. Progress with human H5N1 vaccines: a perspective from industry. Expert Rev Vaccines 2009, 8(April (4)):391-400.
22. Epstein S.L., Price G.E. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 2010, 9(November (11)):1325-1341.
23. Bodewes R., Rimmelzwaan G.F., Osterhaus A.D. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010, 9(January (1)):59-72.
24. Subbarao K., Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007, 3(March (3)):e40.
25. Wrammert J., Koutsonanos D., Li G.M., Edupuganti S., Sui J., Morrissey M., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208(January (1)):181-193.
26. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010, 107(November (44)):18979-18984.
27. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329(August (5995)):1060-1064.
28. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26(June (27-28)):3395-3403.
29. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(April (4)):499-508.
30. Uchida T. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine. Microbiol Immunol 2011, 55(January (1)):19-27.
31. Tissot A.C., Renhofa R., Schmitz N., Cielens I., Meijerink E., Ose V., et al. Versatile virus-like particle carrier for epitope based vaccines. PloS One; 2010, 5(3):e9809.
32. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods (San Diego, CA) 2006, 40(September (1)):60-65.
33. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(December (2)):389-401.
34. Boulay F., Doms R.W., Webster R.G., Helenius A. Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers. J Cell Biol 1988, 106(March (3)):629-639.
35. Chao C.C. A single amino acid deletion at the amino terminus of influenza virus hemagglutinin causes malfolding and blocks exocytosis of the molecule in mammalian cells. J Biol Chem 1992, 267(February (4)):2142-2148.
36. Roy P., Bishop D.H., LeBlois H., Erasmus B.J. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994, 12(July (9)):805-811.
37. Sasagawa T., Pushko P., Steers G., Gschmeissner S.E., Hajibagheri M.A., Finch J., et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995, 206(January (1)):126-135.
38. Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007, 81(July (13)):7111-7123.
39. Chichester J.A, Haaheim L.R., Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev Vaccines 2009, 8(April (4)):493-498.